If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

A list of downloadable documents created during development.

Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

NICE's medicines practice guideline on developing and updating local formularies recommends that medicines recommended in NICE technology appraisals are adopted into local formularies automatically ...

NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...

In SURMOUNT‑1 and SURMOUNT‑2, 2,519 people had tirzepatide alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal disorders ...

Under Regulation 7(5), if NICE considers it appropriate, NICE must specify a longer period if the health technology cannot be appropriately administered until training, additional health service ...